Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia

MA Pulsipher, X Han, SL Maude, TW Laetsch… - Blood Cancer …, 2022 - AACR
We assessed minimal residual disease (MRD) detection and B-cell aplasia after
tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers …
被引用次数：111 相关文章
[HTML] nih.gov

[HTML][HTML] Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute …

MA Pulsipher, X Han, SL Maude… - Blood Cancer …, 2022 - ncbi.nlm.nih.gov
We assessed minimal residual disease (MRD) detection and B-cell aplasia after
tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers …

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic …

MA Pulsipher, X Han, SL Maude… - Blood …, 2022 - scholarlyexchange.childrensmercy …
We assessed minimal residual disease (MRD) detection and B-cell aplasia after
tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers …

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic …

MA Pulsipher, X Han, SL Maude, TW Laetsch… - Blood Cancer …, 2021 - europepmc.org
We assessed minimal residual disease (MRD) detection and B-cell aplasia after
tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers …

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic …

MA Pulsipher, X Han, SL Maude… - Blood cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
We assessed minimal residual disease (MRD) detection and B-cell aplasia after
tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers …

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic …

MA Pulsipher, X Han, SL Maude, TW Laetsch… - Blood Cancer …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title/>< jats: p> We assessed minimal
residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute …

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic …

MA Pulsipher, X Han, SL Maude… - Blood cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
We assessed minimal residual disease (MRD) detection and B-cell aplasia after
tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers …